| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2012-06-06 | Afolia (Follicle Stimulating Hormone [r-FSH]) (biosimilar product) | ovarian stimulation in patients undergoing assisted reproduction technology (ART) | 3 | Finox Biotech (Switzerland) | Gynecology - Women's health |
| 2012-06-05 | masitinib | Gleevec®-resistant gastrointestinal stromal tumors (GIST) | 2 | AB Science (France) | Cancer Oncology |
| 2012-06-05 | TB-402 (Anti-Factor VIII) | prophylaxis of venous thromboembolism (VTE) after total hip surgery |
2b | BioInvent (Sweden) ThromboGenics (Belgium) | Cardiovascular diseases |
| 2012-06-04 | regorafenib (BAY 73-4506) | metastatic and/or unresectable gastrointestinal stromal tumors (GIST) which has progressed after at least imatinib and sunitinib as prior treatments |
3 | Bayer Healthcare (Germany) | Cancer - Oncology |
| 2012-06-04 | trametinib | metastatic melanoma with BRAF V600 mutations | 3 | GSK (UK) | Cancer - Oncology |
| 2012-06-04 | NGR-hTNF | non-small cell lung cancer (NSCLC) | 2 | MolMed (Italy) | Cancer - Oncology |
| 2012-06-04 | NGR-hTNF | relapsed small-cell lung cancer relapsed ovarian cancer |
2 | MolMed (Italy) | Cancer - Oncology |
| 2012-06-04 | POL 103A - sevipromut-L | melanoma | 3 | Polynoma (USA - CA) | Cancer - Oncology |
| 2012-06-04 | Alcover® (sodium oxybate) | Alcohol dependence |
2b-3 | D&A Pharma (France) | CNS diseases - Mental diseases |
| 2012-06-03 | Avastin® (bevacizumab) | metastatic colorectal cancer (mCRC) | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2012-06-02 | Prostvac® (rilimogene) | metastatic castration-resistant prostate cancer (mCRPC) |
2 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2012-06-02 | Avastin® (bevacizumab) | ovarian cancer |
3 | Roche (Switzerland) | Cancer - Oncology |
| 2012-06-01 | Aubagio™ (teriflunomide) | relapsing multiple sclerosis | 3 | Genzyme (USA - MA), a Sanofi company (France) | Autoimmune diseases - Neurodegenerative diseases |
| 2012-06-01 | IMA910 | advanced colorectal cancer | 2 | immatics biotechnologies (Germany) | Cancer - Oncology |
| 2012-05-30 | ALKS 37 | opioid-induced constipation |
2b | Alkermes (USA - Ireland) | Digestive diseases |
| 2012-05-29 | combination of VX-809 and Kalydeco® (ivacaftor) | cystic fibrosis |
2 | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2012-05-28 | APD421 (intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) | prevention of post-operative nausea & vomiting (PONV) | 2 | Acacia Pharma (UK) | Digestive diseases |
| 2012-05-28 | Huntexil® (pridopidine, previously designated ACR16) | Huntington's disease | Neurosearch (Denmark) | Genetic diseases - Neurodegenerative diseases - Rare diseases | |
| 2012-05-26 | SAR236553/REGN727 | heterozygous familial hypercholesterolemia |
2 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Genetic diseases - Rare diseases |
| 2012-05-24 | cell culture based pandemic flu vaccine co-developed with GlaxoSmithKline (GSK) and using Vivalis’ EB66® cell line | pandemic influenza | 2 | Kaketsuken (Japan) | Infectious diseases |
